1. Introduction {#s0005}
===============

Postpartum depression (PPD) is characterized as major depressive disorder with an onset of symptoms occurring between delivery and one year postpartum ([@bb0090]). With a prevalence of 10--15% ([@bb0180]), PPD is costly and debilitating, affecting women\'s quality of life, social functioning and productivity ([@bb0170]). Left untreated, PPD increases the risk of negative consequences for the mother, child, and family ([@bb0055]; [@bb0125]; [@bb0120]). PPD is also associated with increased health service utilization ([@bb0080]; [@bb0170]). According to the 2009 Institute of Medicine Report, greater service utilization tracking is required for mothers with PPD and children to better understand the relationship between required and unrequired resource use ([@bb0170]; [@bb0040]).

Screening has the potential to identify symptoms related to undiagnosed PPD that would otherwise remain untreated or be treated at a later, more severe, stage ([@bb0170]; [@bb0095]). Early identification through routine screening has the ability to improve timely PPD care and optimize family well-being ([@bb0170]; [@bb0010]) while potentially reducing costs at a health system level ([@bb0095]). However, globally, inconsistencies exist in routine screening recommendations, including the use of specific screening instruments and cut-off scores ([@bb0170]). Further, evidence is poor regarding rates of PPD diagnosis and treatment subsequent to screening ([@bb0240]; [@bb0235]; [@bb0215]). The Canadian Task Force for Preventive Health Care does not recommend routine screening for perinatal depression in primary care settings ([@bb0100]), whereas the National Institute for Health and Care Excellence encourages the use of two-question screening where indicated ([@bb0210]), and clinical practice recommendations in the United States encourage universal screening when appropriate supports are in place ([@bb0045]; [@bb0070]).

1.1. Screening pathway for PPD in Alberta, Canada {#s0010}
-------------------------------------------------

In Alberta, Canada, public health nurses use the Edinburgh Postnatal Depression Scale (EPDS) to opportunistically screen women during their first regular well child clinic visit, unless there is an indication to screen earlier ([@bb0005]). The EPDS is a 10-item self-administered tool that takes \<15 min to complete and provides public health nurses with a quantifiable and interpretable score ([@bb0050]; [@bb0135]; [@bb0205]). As the most widely used instrument for PPD screening, the EPDS is available in several languages ([@bb0170]; [@bb0140]; [@bb0145]; [@bb0175]; [@bb0205]). Using a cut-off of 12/13, sensitivity is reported to range from 0.67 to 1.00 and specificity at 0.87 or more ([@bb0175]). At the time of this study, a score of 0--10 (of 30) on the EPDS indicated low-risk, 11 indicated moderate-risk and a score of 12 or greater indicated high-risk for PPD. Public health nurses used this criteria as a guide for their conversations, where women were informed about available resources and services, and, if high-risk, offered referral to her family physician for further diagnosis and treatment ([@bb0005]). Of note, women within the moderate-risk range for PPD may or may not be referred to her family physician for care, as this decision is left at the discretion of the public health nurse ([@bb0005]).

The objective of the current study was to examine the effectiveness of screening in identifying, diagnosing and treating women at increased risk for PPD over the first year postpartum, compared to those unscreened. Linked administrative data was used to determine PPD and non-PPD related health utilization patterns and to examine the association between PPD screening and 1) diagnosis and 2) mental health drugs dispensed up to 12 months postpartum, while controlling for sociodemographic characteristics and other risk factors for PPD. We considered screening *effective* if women screened high-risk were more likely to receive a PPD diagnosis, had higher PPD-related utilization and mental health drugs dispensed. Although effectiveness has been operationalized this way before ([@bb0240]), to our knowledge this is the first study examining PPD screening effectiveness in this manner using linked administrative data in a Canadian perinatal sample.

2. Methods {#s0015}
==========

Ethics approval was received from the Conjoint Health Research Ethics Board, University of Calgary (Ethics ID 140427).

The All Our Families (AOF; n = 3387) study was established in 2008 as a community-based pregnancy cohort grounded in Calgary, Alberta, and designed to examine early life influences on child development and family well-being ([@bb0150]). Recruitment, eligibility, and data collection for the cohort have been previously reported ([@bb0150]; [@bb0220]). Briefly: expectant women were recruited for the cohort between 2008 and 2011 prior to reaching 25 weeks\' gestation, using a multi-method recruitment strategy involving community posters, primary health centres and city-wide public health laboratory services ([@bb0150]). Two questionnaires were completed during pregnancy, two during the first postpartum year (at 4 and 12 months postpartum), and when children were two, three, and five years of age; data collection is ongoing for the eight year questionnaire ([@bb0220]).

2.1. Data linkage and sample {#s0020}
----------------------------

Women\'s self-reported demographic and other characteristics were obtained from AOF and linked using unique identifiers to public health data that contained information on EPDS screening and referral status. Data were further linked to physician claims, inpatient, outpatient, and community pharmaceutical databases to support identification of PPD diagnoses, PPD and non-PPD related utilization, and pharmacological treatment patterns ([Fig. 1](#f0005){ref-type="fig"}). Diagnosis and treatment status were examined up to 12 months postpartum subsequent to being offered screening; utilization was examined for the entire first year postpartum. Given that screening is an approach designed to capture women not yet diagnosed with PPD ([@bb0215]), women were eligible for this study if they 1) were not receiving community pharmaceutical treatment for depression at the time of screening and 2) had no history of depression in the current pregnancy prior to screening; both were determined by examining PPD diagnostic information and mental health drugs dispensed to women between the date of delivery and date of screening. After removal of women with erroneous or missing unique identifiers and application of the eligibility criteria, the final sample was 2698.Fig. 1Administrative data linkage.Fig. 1

2.2. Research objective and questions {#s0025}
-------------------------------------

The objective of the current study was to examine the effectiveness of screening in identifying, diagnosing and treating women at increased risk for PPD over the first year postpartum. Specific research questions included:1.What are the patterns of PPD and non-PPD healthcare utilization for each screening category over the first year postpartum?2.Is there an association between screening category and PPD diagnosis over the first year postpartum?3.Is there an association between screening category and mental health drugs dispensed over the first year postpartum?

2.3. Exposure and outcome variables {#s0030}
-----------------------------------

Our primary exposure variable was screening status at two months postpartum. Using public health data, women\'s EPDS scores were obtained and they were categorized as being low/moderate-risk for PPD (scores 0--11), high-risk for PPD (scores ≥12), or unscreened. Outcome variables included PPD diagnosis and mental health drugs dispensed over the first year postpartum.

Psychiatrists and perinatal mental health experts identified and finalized the mental health codes included in the case definition for PPD ([Appendix 1](#ec0005){ref-type="supplementary-material"}). Similar to [@bb0075], the team incorporated a broad range of mental health ICD codes comprising perinatal distress. These codes included six diagnostic categories: episodic mood disorder, anxiety disorder, stress reaction, adjustment reaction, depressive disorder, and other mood disorders. PPD *diagnosis* was defined using the 1 hospitalization, 2 physician claims (1H2P) method over a one year period, validated for hypertension and adopted by Health Canada in their Canadian Chronic Disease Surveillance System ([@bb0190]; [@bb0015]). PPD *treatment* was defined according to whether a mental health drug recommended through Canadian treatment guidelines was dispensed to women within the first year postpartum ([@bb0115]; [@bb0020]; [@bb0110]). PPD and non-PPD related *utilization* were defined as the number of physician, inpatient, and outpatient visits, and unique drugs dispensed between birth and 12 months postpartum. Of note: all PPD-related utilization took place following a woman\'s screening date (if they were screened) or following delivery (if they were unscreened), in accordance with the eligibility criteria.

2.4. Statistical analysis {#s0035}
-------------------------

Descriptive statistics were produced using means and standard deviations (SD), medians and interquartile ranges (IQR), or frequencies, proportions and 95% confidence intervals (CI). Chi-square, Kruskal-Wallis non-parametric and analysis of variance (ANOVA) parametric tests examined differences in sample characteristics and PPD and non-PPD related utilization by screening category. Odds ratios (ORs) and 95% CI for PPD diagnosis and mental health drugs dispensed were generated using crude and multivariable logistic regression models. For the diagnosis and mental health drugs dispensed models, the unscreened category constituted the reference group in line with the Canadian guideline systematic literature review criteria, which supports quasi-experimental studies with an unscreened group ([@bb0100]). Covariates entered in the initial models included maternal age, income, parity, ethnicity, self-reported maternal history of depression and comorbidities. We examined comorbidities as these increase the likelihood of healthcare utilization ([@bb0030], [@bb0035]). We used the enhanced version of the Charlson comorbidity index in physician claims data and the Quan version for inpatient and outpatient data to identify the presence of medical comorbidities, such as diabetes, cancer, or cardiovascular disease, over the first year postpartum ([@bb0025]). A binary variable was generated using the information retrieved from the index to categorize women as having or not having medical comorbidities. Statistical significance was set at p \< 0.05. All variables of interest were included in the multivariable analysis and a manual backwards stepwise approach was used to arrive at final, parsimonious regression models. Data linkage, cleaning and analysis took place using Stata 15 (Stata Corp. 2015. Stata Statistical Software: Release 15. College Station, TX, USA: Stata Corp LP).

3. Results {#s0040}
==========

Women were, on average, 31 years old and 89% had completed some college, university or graduate school ([Table 1](#t0005){ref-type="table"}). Ninety-five percent were married or common-law, and two-thirds had a household income of \$80,000 or more. The majority of participants were born, or had lived, in Canada \>5 years (89%), while 78% were Caucasian. Of the women in our sample, 2261 (84%) received a low/moderate-risk score for PPD and 78 (3%) received a high-risk score. Thirteen percent of women were unscreened. Of those screened as high-risk, two-thirds were screened between two and four months postpartum and one-third were screened prior to two months postpartum ([Fig. 2](#f0010){ref-type="fig"}). Among those screened as low/moderate-risk for PPD, three-quarters were screened between two and four months postpartum, while 19% were screened prior to two months postpartum. Those screened as high-risk visited their physician for a PPD-related reason at a median of 21 days post screen (IQR: 56), while those screened low/moderate-risk visited their physician for a PPD-related reason at a median of 112 days post screen (IQR: 132) and unscreened women visited their physician for a PPD-related reason at a median of 50 days post-delivery (IQR: 129; p \< 0.0001).Table 1Sample characteristics.Table 1Full sample (n = 2698)Low/moderate-risk (n = 2261)High-risk (n = 78)Unscreened (n = 359)p-ValueMean (SD)Maternal age at delivery31.25 (4.40)31.16 (4.35)30.89 (4.69)31.89 (4.59)**0.015**Educationn (%, 95% CI) High school or less275 (10.2, 9.08--11.4)236 (10.4, 9.2--11.8)11 (14.1, 7.3--23.8)28 (7.8, 5.2--11.1)0.139 Some or complete university/college1975 (73.2, 71.5--74.9)1648 (72.9, 71.0--74.7)57 (73.1, 61.8--82.5)270 (75.2, 70.4--79.6) Some or complete graduate school412 (15.3, 13.9--16.7)346 (15.3, 13.8--16.9)6 (7.7, 2.9--16.0)60 (16.7, 13.0--21.0)Marital status Married/common law2559 (94.8, 93.9--95.7)2148 (95.0, 94.0--95.9)74 (94.9, 87.4--98.6)337 (93.9, 90.7--96.1)0.482 Other126 (4.7, 3.9--5.5)101 (4.5, 3.7--5.4)4 (5.1, 1.4--12.6)21 (5.8, 3.7--8.8)Income (annual household) \<\$40,000212 (7.9, 6.9--8.9)157 (6.9, 5.9--8.1)13 (16.7, 9.2--26.8)42 (11.7, 8.6--15.5)**\<0.001** \$40,000--\$79,999548 (20.3, 18.8--21.9)448 (19.8, 18.2--21.5)15 (19.2, 11.2--29.7)85 (23.7, 19.4--28.4) ≥\$80,0001821 (67.5, 65.7--69.3)1557 (68.9, 66.9--70.8)44 (56.4, 44.7--67.6)220 (61.3, 56.0--66.3)Time in Canada Born in Canada/lived here ≥5 years2390 (88.6, 87.3--89.8)2013 (89.0, 87.7--90.3)63 (80.8, 70.3--88.8)314 (87.5, 83.6--90.7)0.067 Lived in Canada \<5 years261 (9.7, 8.6--10.9)207 (9.2, 8.0--10.4)12 (15.4, 8.2--25.3)42 (11.7, 8.6--15.5)Parity Primaparous1316 (48.8, 46.9--50.7)1133 (50.1, 48.0--52.2)37 (47.4, 36.0--59.1)146 (40.7, 35.5--45.9)**0.002** Multiparous1330 (49.3, 47.4--51.2)1083 (47.9, 45.8--50.0)38 (48.7, 37.2--60.3)209 (58.2, 52.9--63.4)Ethnicity White/Caucasian2096 (77.7, 76.1--79.2)1761 (77.9, 76.1--79.6)49 (62.8, 51.1--73.5)286 (79.7, 75.1--83.7)**0.014** Other566 (21.0, 19.4--22.6)469 (20.7, 19.1--22.5)26 (33.3, 23.1--44.9)71 (19.8, 15.8--24.3)Fig. 2Timing of PPD screen and proportion scored low/moderate-risk or high-risk, with 95% CI.Fig. 2

Within our sample, high-risk women were slightly younger compared to those identified as low/moderate-risk or unscreened (p = 0.015). No differences by screening category existed in terms of education, marital status or time in Canada. However, women with lower income were more likely to score high-risk for PPD or be unscreened (p \< 0.001), multiparous women were more likely to be unscreened (p = 0.002) and non-Caucasian women were more likely to receive a high-risk PPD score (p = 0.014).

3.1. Utilization patterns {#s0045}
-------------------------

[Table 2](#t0010){ref-type="table"} presents PPD and non-PPD related utilization among women over the first year postpartum. Overall, PPD-related utilization was associated with screening category for all types of health services; 51% of women screened high-risk visited their physician at least once for a PPD-related reason, compared to 16% of women screened low/moderate-risk and 17% of those unscreened (p \< 0.001). Similarly, 9% of those screened high-risk had at least one PPD-related outpatient visit, compared to \<2% of those screened low/moderate-risk and unscreened (p \< 0.001), and 18% of women screened high-risk received a mental health drug compared to 5% of women screened low/moderate-risk and 9.5% of those unscreened (p \< 0.001).Table 2PPD and non-PPD related utilization among women in the first year postpartum.Table 2Low/moderate-risk\
(n = 2261)\
n (%, 95% CI)High-risk\
(n = 78)\
n (%, 95% CI)Unscreened\
(n = 359)\
n (%, 95% CI)p-ValueUtilization for PPD-related reasonPhysician visits 0 claims1893 (83.7, 82.1--85.2)38 (48.7, 37.2--60.3)297 (82.7, 78.4--86.5)**\<0.001** 1 claim228 (10.1, 8.9--11.4)14 (18.0, 10.2--28.3)20 (5.6, 3.4--8.5) 2 claims61 (2.7, 2.1--3.5)6 (7.7, 2.9--16.0)12 (3.3, 1.7--5.8) 3+ claims79 (3.5, 2.8--4.3)20 (25.6, 16.4--36.8)30 (8.4, 5.7--11.7)Outpatient visits 0 visits2248 (99.4, 99.0--99.7)71 (91.0, 82.4--96.3)352 (98.1, 96.0--99.2)**\<0.001** 1 visit5 (0.2, 0.1--0.5)1 (1.3, 0--6.9)1 (0.3, 0--1.5) 2 visits1 (0, 0--0.2)2 (2.6, 0.3--9.0)2 (0.6, 0--2.0) 3+ visits7 (0.3, 0.1--0.6)4 (5.1, 1.4--12.6)4 (1.1, 0.3--2.8)Inpatient visits[a](#tf0005){ref-type="table-fn"} 0 visits2261 (100, 99.8--100)77 (98.7, 93.1--100)357 (99.4, 98.0--99.9)**\<0.001** 1 visit01 (1.3, 0--6.9)2 (0.6, 0.1--2.0) 2 visits000 3+ visits000Mental health drugs dispensed (unique prescriptions only) 0 drugs2144 (94.8, 93.8--95.7)64 (82.0, 71.7--89.8)325 (90.5, 87.0--93.4)**\<0.001** 1 drug72 (3.2, 2.5--4.0)9 (11.5, 5.4--20.8)21 (5.8, 3.7--8.8) 2 drugs27 (1.2, 0.8--1.7)2 (2.6, 0.3--9.0)6 (1.7, 0.6--3.6) 3+ drugs18 (0.8, 0.5--1.3)3 (3.8, 0.8--10.8)7 (1.9, 0.8--4.0)  Utilization for non-PPD related reasonPhysician claims 0 claims000**0.003** 1 claim8 (0.4, 0.1--0.7)07 (1.9, 0.8--4.0) 2 claims8 (0.4, 0.1--0.7)00 3+ claims2245 (99.2, 98.9--99.6)78 (100, 95.4--100)352 (98.1, 96.4--99.4)Outpatient visits 0 visits753 (33.3, 31.4--35.3)26 (33.3, 23.1--44.9)109 (25.4, 25.6--35.4)0.062 1 visit850 (37.6, 35.6--39.6)26 (33.3, 23.1--44.9)128 (35.6, 30.7--40.9) 2 visits325 (14.4, 13.0--15.9)6 (7.7, 2.9--16.0)60 (16.7, 13.0--21.0) 3+ visits333 (14.7, 13.3--16.3)20 (25.6, 16.4--36.8)62 (17.2, 13.5--21.6)Inpatients visits[a](#tf0005){ref-type="table-fn"} 0 visits2182 (96.5, 95.7--97.2)76 (97.4, 91.0--99.7)341 (95.0, 92.2--97.0)0.240 1 visit37 (1.6, 1.2--2.2)2 (2.6, 0.3--9.0)6 (1.7, 0.6--3.6) 2 visits000 3+ visits42 (1.9, 1.3--2.5)012 (3.3, 1.7--5.8)Drugs dispensed (unique prescriptions only) 0 drugs2154 (95.3, 94.3--96.1)66 (84.6, 74.7--91.8)326 (90.8, 87.3--93.6)**\<0.001** 1 drug9 (0.4, 0.2--0.8)03 (0.8, 0.2--2.4) 2 drugs16 (0.7, 0.4--1.1)4 (5.1, 1.4--12.6)3 (0.8, 0.2--2.4) 3+ drugs82 (3.6, 2.9--4.5)8 (10.3, 4.5--19.2)27 (7.5, 5.0--10.8)[^1]

Screening category was significantly associated with non-PPD related utilization for physician visits and non-mental health drugs dispensed. Fifteen percent of women who screened high-risk, compared to 5% of those who screened low/moderate-risk and 9% of those unscreened received a non-mental health related drug over the first year postpartum (p \< 0.001).

3.2. Multivariable regression analysis results {#s0050}
----------------------------------------------

Overall, 8% of the sample was diagnosed with PPD, including 37% of women screened high-risk, 6% screened low/moderate-risk, and 12% of women that were unscreened (p \< 0.001). Compared to those unscreened, women screened high-risk were more likely to receive a PPD diagnosis over the first year postpartum (OR: 3.88, 95% CI: 2.18--6.92; [Table 3](#t0015){ref-type="table"}), whereas those screened low/moderate-risk had a 49% reduction in their likelihood of being diagnosed with PPD (OR: 0.51, 95% CI: 0.35--0.74). Further, women screened low/moderate-risk, compared to those unscreened, were half as likely to receive a mental health drug over the first year postpartum (OR: 0.53, 95% CI: 0. 36--0.80), whereas those screened high-risk were equally likely to receive a mental health drug as those unscreened (OR: 1.73, 95% CI: 0.86--3.46).Table 3Multivariable regression model results.Table 3Crude OR (95% CI)Adjusted OR (95% CI)[a](#tf0010){ref-type="table-fn"}Outcome: PPD diagnosisScreening status Screened high-risk**4.47 (2.56--7.83)3.88 (2.18--6.92)** Screened low-risk**0.50 (0.35--0.72)0.51 (0.35--0.74)** Unscreened1.001.00Lifetime history of depression Yes--**3.01 (2.25--4.03)** No--1.00Presence of comorbidities[b](#tf0015){ref-type="table-fn"} Yes--**1.78 (1.15--2.75)** No--1.00  Outcome: mental health drugs dispensedScreening status Screened high-risk1.98 (0.99--3.97)1.73 (0.86--3.46) Screened low-risk**0.51 (0.34--0.76)0.53 (0.36--0.80)** Unscreened1.001.00Lifetime history of depression Yes--**2.96 (2.15--4.09)** No--1.00Presence of comorbidities[b](#tf0015){ref-type="table-fn"} Yes--**1.88 (1.18--3.00)** No--1.00[^2][^3]

4. Discussion {#s0055}
=============

In our study, screening appeared to effectively separate the high-risk from low/moderate-risk women and to streamline resources between these groups; women screened low/moderate-risk had lower PPD and non-PPD related utilization, on average, compared to those screened high-risk. These results align with previous research on this topic, which found that women with depression symptomology were high utilizers of family physician services in the first two months postpartum ([@bb0060]). Women screened high-risk also followed-up with their physician for a PPD-related reason much more quickly post-screen and were more likely to be diagnosed with PPD compared to those unscreened, which also aligns with other studies of a similar nature ([@bb0230]; [@bb0130]; [@bb0240]).

Of those unscreened, 17% of women saw a physician at least once for a PPD-related visit and, compared to those identified as high-risk, were equally likely to receive a mental health drug over the first year postpartum, indicating they may have experienced symptoms of PPD despite being unscreened. This suggests there could be a missed opportunity for those who are unscreened whereby they may require additional opportunities for care or alternative screening, such as easy access clinics or a brief screen rather than a 10-item scale ([@bb0085]). Although reasons for being unscreened were inconsistently recorded in our data, further research examining reasons for not screening would be valuable to better understand utilization patterns among this group.

High-risk women appeared to have greater non-PPD related physician claims and drug utilization compared to those within the low/moderate-risk range and those that were unscreened, although it is unlikely that the differences in non-PPD related physician claims are clinically significant despite being statistically significant. Women with a high-risk score also had an indication of higher non-PPD related outpatient utilization, supporting the need to better understand whether their overall utilization was appropriate and necessary, as identified in the literature ([@bb0170]; [@bb0040]; [@bb0060]; [@bb0195]; [@bb0185]). The Charlson comorbidity index does not identify pregnancy and postpartum conditions, which made it difficult to determine whether women were appropriately receiving care for postpartum complications ([@bb0025]). Additional research to better understand these patterns over a longer period of time is warranted. Results from our multivariable analysis further confirmed that marital status, socioeconomic status, and parity were not generally associated with PPD once other factors were taken into consideration, whereas history of depression was moderately associated with PPD, as identified through previous research ([@bb0170]; [@bb0010]), and women with comorbidities also had an increased risk for a PPD diagnosis compared to women without. This also aligns with findings from the literature ([@bb0165]; [@bb0105]).

According to our findings, of those screened high-risk, only 51% had a visit with a physician for a PPD-related reason. While screening itself may increase awareness and potentially prompt some women to seek help from sources other than her physician, for example through peer support, internet-based self-help or phone support ([@bb0120]), low physician visit rates among those screened high-risk may be alleviated through increased communication between public health and primary care around PPD risk scores, decreasing women\'s risk of not receiving appropriate follow-up care subsequent to her high-risk screening score. This is further supported within the literature, where women have noted their frustration with disconnected care pathways and have indicated they would prefer to be contacted and supported by their family physicians following a public health screen ([@bb0205]; [@bb0120]).

4.1. Strengths and limitations {#s0060}
------------------------------

Strengths of this study included the use of linked survey and administrative data, which enabled us to conduct a pragmatic evaluation of screening effectiveness ([@bb0225]). Application of our exclusion criteria also allowed for isolation of the screening exposure, a design recommendation for examination of efficacy ([@bb0215]; [@bb0100]). Despite these strengths, there are limitations to this study. Over 600 women from AOF were not linked to the administrative data. Analysis showed that those not linked had lower levels of education and income and were less likely to be partnered, raising the potential for selection bias. However, this likely underestimates the effects found in our study. Of note, 'low education and income' in our study identifies women who are under the median annual income of \$80,000; it could be that not having a safety net or making ends meet in an affluent urban climate creates a context of added stress for these families. Further supports such as postpartum peer support and community engagement are worthy of exploration given their importance in previous work with this cohort ([@bb0155]; [@bb0160]). Another limitation is the potential for non-differential misclassification of exposure and outcome status due to coding and/or data entry errors; this would also lead to an underestimate of effects found in this study. Although the literature supports using the Charlson comorbidity index to control for confounding in epidemiological data, it has traditionally been used to predict mortality risk, healthcare utilization and costs ([@bb0200]). The validity of using this index to adjust for the presence versus absence of comorbidities is a potential direction for future research. Additionally, only 3% of those in our sample were screened high-risk for PPD. This is a great deal lower than the prevalence of PPD in the general population, reported to be between 10 and 15% ([@bb0180]), and suggests a much lower sensitivity for the EPDS than is reported elsewhere ([@bb0175]). Future research should focus on assessing the adequacy of the cut-off score in Canadian women. Lastly, although the literature suggests women prefer non-pharmaceutical treatment for PPD ([@bb0065]), we were unable to evaluate whether women received this type of treatment in our study. Future work examining PPD screening and non-pharmaceutical treatment patterns among Albertan women may be warranted.

5. Conclusion {#s0065}
=============

The present study provides encouraging evidence for the effectiveness of PPD screening in Alberta; women screened high-risk were more likely to receive a PPD diagnosis and had higher PPD-related utilization and drugs dispensed compared to those unscreened. Future work should focus on evaluating the cost-effectiveness of screening across the entire treatment pathway.

The following is the supplementary data related to this article.Appendix 1PPD case definition.Appendix 1
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[^1]: Excludes visits for a labour and delivery reason (ICD10: Z37).

[^2]: Variables of interest entered in the initial models included maternal age, income, parity, ethnicity, lifetime history of depression and comorbidity.

[^3]: Presence of comorbidities defined using the Charlson comorbidity index applied to physician claims, inpatient and outpatient data.
